Altimmune Valuation
Is ALT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Share Price vs Fair Value
What is the Fair Price of ALT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALT?
Key metric:
| What is ALT's PB Ratio? | |
|---|---|
| PB Ratio | 3.5x |
| Book | US$133.38m |
| Market Cap | US$472.27m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6435.8x |
| Enterprise Value/EBITDA | -3.4x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ALT's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.8x | ||
KROS Keros Therapeutics | 0.9x | -1.0% | US$461.8m |
MREO Mereo BioPharma Group | 6.4x | 60.7% | US$466.2m |
SAGE Sage Therapeutics | 0.8x | 39.4% | US$443.5m |
LENZ LENZ Therapeutics | 3.3x | 44.3% | US$702.1m |
ALT Altimmune | 3.5x | 27.6% | US$472.3m |
Price to Book Ratio vs Industry
How does ALT's PB Ratio compare vs other companies in the US Biotechs Industry?
Price to Book Ratio vs Fair Ratio
What is ALT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 3.5x |
| Fair PB Ratio | n/a |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 03:44 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Altimmune, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Joshua Schimmer | Evercore ISI |
| Liisa Bayko | Evercore ISI |